News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics provides status update of the pivotal study with Emcitate

June 30, 2021

Egetis Therapeutics AB (publ) (ticker: EGTX) today provided a status update of its leading candidate drug Emcitate where patient recruitment to the Phase IIb/III study TRIAC II is progressing according to plan.

Patient recruitment to the TRIAC II study with Emcitate is progressing well, and the recruitment is expected to be completed in Q4 2021, in line with previous communication.
 
“I am happy to announce that we continue to recruit patients to the study according to plan. Interim results are targeted to be available in H2 2022 and will be an important step towards regulatory approvals and commercial launch”, said Nicklas Westerholm, CEO of Egetis Therapeutics.
 
Emcitate, which has Orphan Drug Designation (ODD) in both EU and the US and received a US Rare Pediatric Disease designation (RPD) in November 2020, is developed for the treatment of MCT8 deficiency, a rare congenital disorder of thyroid hormone trafficking with detrimental natural history and no currently available therapy. Approximately 1 in 70,000 males are affected.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com